Gapping up
In reaction to earnings/guidance:
- WFRD +4.3% (guidance) MATX +3.9% (guides Q3 EPS above dual analyst consensus), AAL +0.4% (guidance)
Other news:
- TARA +19.4% (announces FDA clearance of investigational new drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer)
- QTRX +12.8% (receives Breakthrough Device designation from the FDA for Simoa pTau-181 blood test)
- SLI +10% (announces positive preliminary economic assessment)
- WWR +9.2% (provides results from Definitive Feasibility Study)
- PSTX +8.9% (announces research collaboration and exclusive license agreement with Takeda Pharmaceutical (TAK) )
- TIPT +6.9% (announced a $200 million strategic investment in its insurance subsidiary, The Fortegra Group from Warburg Pincus)
- IFRX +6.7% (completes enrollment of Vilobelimab Phase III study in severe COVID-19 )
- AERI +6.4% (reports Phase 3 topline results for Netarsudil Ophthalmic solution 0.02% clinical trial in Japan)
- PAGS +4.4% (Board of Directors has appointed Mr. Alexandre Magnani as Chief Operating Officer)
- GERN +3.7% (announces publication of analyses comparing real world data to IMbark Phase 2)
- SIG +3.1% (to acquire Diamonds Direct USA for $490 mln in an all cash transaction; raises guidance)
- NRXP +2.9% (announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI (aviptadil) was submitted to the FDA)
- XP +2.6% (reports performance highlights for Q3)
- TGB +2% (reports Q3 copper production increased 29%)
Analyst comments:
- ABNB +2.4% (upgraded to Outperform from Market Perform at Cowen)
- GFI +2.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- KEX +1.8% (upgraded to Buy from Hold at Stifel)
- AYI +1.1% (upgraded to Neutral from Sell at UBS)